MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.
MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH".
MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.
Location: United States, California, Irvine
Funding Rounds 2
Mentions in press and media 43